Posts

API & IP Brief: Dr. Reddy’s Patent Landscape, Semaglutide Revocation & Voquezna Updates

Image
API & IP Intelligence Brief: Dr. Reddy’s Patent Strategy & Semaglutide Patent Revocation Keywords: Dr. Reddy's patent filings, Semaglutide patent revocation, EPO Board of Appeal T 0187/25, Factor XIa inhibitors, API solid-state forms, skinny label generic, Voquezna ANDA litigation . Dr. Reddy’s Patent Landscape: Early-Stage Generic Positioning An analysis of 24 patent applications published between October 2024 and October 2026 highlights Dr. Reddy’s Laboratories’ (DRL) aggressive pre-loss-of-exclusivity (LOE) strategy . Small-molecule generic enablement accounts for 67% (16 filings) of the total, divided between API process/solid-state chemistry (38%, 9 filings) and differentiated dosage forms (29%, 7 filings) . The remaining pipeline spans biologics (13%), nutraceuticals (8%), digital health (8%), and a single new chemical entity (NCE) pan-KRAS degrader filing from Aurigene Oncology (4%) . DRL is building alternative crystal forms, salts, amorphous solid dispersion...
Read more

FDA Q3 2026 DMF Filings, Delhi HC Patent Ruling & Biocon BPCIA Settlement

Image
Summary: 5-minute read The latest intelligence update covers US FDA Drug Master File (DMF) trends for Q3 2026, landmark pharmaceutical IP jurisprudence from the Delhi High Court, and key regulatory and biosimilar litigation settlements . 1. US FDA Q3 2026 Type II DMF Filings Landscape A total of 316 Type II (Drug Substance) DMFs were submitted in Q3 2026, with India and China accounting for over 85% of total volume : Geographic Distribution: China led with 148 filings (47%), prioritising peptide therapeutics (Semaglutide, Tirzepatide, Orforglipron), exosomes, and bioprocessing media . India followed with 123 submissions (39%), focusing on small-molecule oncology kinase inhibitors, cardiometabolic therapies, and complex anti-infectives . The US and Rest of World accounted for 5% (17) and 9% (28), respectively . Top Filing Entities: Suyog Life Sciences topped the rankings with 11 filings (primarily key starting materials and advanced intermediates), followed by Apitoria Pharma...
Location: Mumbai, Maharashtra, India
Read more